*In postmenopausal women.
HER2–, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; mTORi, mammalian target of rapamycin
inhibitor; NSAI, non-steroidal aromatase inhibitor.
1. Everolimus
®
Prescribing Information 2014; 2. Shah P, Dickler M.
Clin Adv Hematol Oncol
2014;12:214–24.
PI3K pathway activation
can cause resistance to
therapy
2
Fulvestrant
Approved for HR+ mBC*
that has progressed on
anti-estrogen therapy
2
? ?
? ? ?
The combination of buparlisib and fulvestrant may be a treatment option in
HR+/HER2– mBC patients* who have relapsed after mTORi-based therapy
Postmenopausal
women with
HR+/HER– mBC
Everolimus
+
exemestane
NSAI
Everolimus has been approved for use in postmenopausal women with
HR+/HER2– mBC whose disease has progressed on a NSAI
1
Despite improved
outcomes, many patients
develop resistance to
everolimus
No specific treatments
following progression on
mTORi-based therapy
1
6
0
9
0
4
3
6
8
1
